Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia von Andreeff, Michael, Kelly, Kevin R, Yee, Karen, Assouline, Sarit, Strair, Roger, Popplewell, Leslie, Bowen, David, Martinelli, Giovanni, Drummond, Mark W, Vyas, Paresh, Kirschbaum, Mark, Iyer, Swaminathan Padmanabhan, Ruvolo, Vivian, González, Graciela M Nogueras, Huang, Xuelin, Chen, Gong, Graves, Bradford, Blotner, Steven, Bridge, Peter, Jukofsky, Lori, Middleton, Steve, Reckner, Monica, Rueger, Ruediger, Zhi, Jianguo, Nichols, Gwen, Kojima, Kensuke

Volltext

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2 -amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism stu... von Ray-Coquard, Isabelle, Dr, Blay, Jean-Yves, Prof, Italiano, Antoine, MD, Le Cesne, Axel, MD, Penel, Nicolas, MD, Zhi, Jianguo, PhD, Heil, Florian, PhD, Rueger, Ruediger, MD, Graves, Bradford, PhD, Ding, Meichun, PhD, Geho, David, MD, Middleton, Steven A, PhD, Vassilev, Lyubomir T, PhD, Nichols, Gwen L, MD, Bui, Binh Nguyen, MD

Volltext

Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts von Reis, Bernhard, Jukofsky, Lori, Chen, Gong, Martinelli, Giovanni, Zhong, Hua, So, W Venus, Dickinson, Michael J, Drummond, Mark, Assouline, Sarit, Hashemyan, Maneja, Theron, Michel, Blotner, Steven, Lee, Je-Hwan, Kasner, Margaret, Yoon, Sung-Soo, Rueger, Ruediger, Seiter, Karen, Middleton, Steven A, Kelly, Kevin R, Vey, Norbert, Yee, Karen, Nichols, Gwen, Chen, Lin-Chi, Pierceall, William E

Volltext

Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor von Stahl, Sebastian, Seidl, Ana Rita da Silva Mateus, Ducret, Axel, van Geijtenbeek, Sabine Kux, Michel, Sven, Racek, Tomas, Birzele, Fabian, Haas, Alexander K., Rueger, Ruediger, Gerg, Michael, Niederfellner, Gerhard, Pastan, Ira, Brinkmann, Ulrich

Volltext

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma von Ang, Joo Ern, Pal, Akos, Asad, Yasmin J, Henley, Alan T, Valenti, Melanie, Box, Gary, de Haven Brandon, Alexis, Revell, Victoria L, Skene, Debra J, Venturi, Miro, Rueger, Ruediger, Meresse, Valerie, Eccles, Suzanne A, de Bono, Johann S, Kaye, Stanley B, Workman, Paul, Banerji, Udai, Raynaud, Florence I

Volltext

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker von LEE, Lucy, HUIFENG NIU, GOELZER, Petra, DE SCHEPPER, Stefanie, YOSHIMURA, Yashushi, BARRETT, Joanne, ISHIKAWA, Yuji, WEISSGERBER, Georges, PECK, Richard, RUEGER, Ruediger, IGAWA, Yuriko, DEUTSCH, Jonathan, ISHII, Nobuya, SONG MU, SAKAMOTO, Yuuichiro, BUSSE-REID, Rachel, GIMMI, Claude

Volltext

Long Non-coding RNAs and their Role in Metastasis von Weidle, Ulrich H, Birzele, Fabian, Kollmorgen, Gwen, Ruger, Rudiger

Volltext

Mechanisms and Targets Involved in Dissemination of Ovarian Cancer von Weidle, Ulrich H, Birzele, Fabian, Kollmorgen, Gwendlyn, Rueger, Rudiger

Volltext

The Multiple Roles of Exosomes in Metastasis von Weidle, Ulrich H, Birzele, Fabian, Kollmorgen, Gwen, Ruger, Rudiger

Volltext

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients von Berkofsky-Fessler, Windy, Nguyen, Tri Q., Delmar, Paul, Molnos, Juliette, Kanwal, Charu, DePinto, Wanda, Rosinski, James, McLoughlin, Patricia, Ritland, Steve, DeMario, Mark, Tobon, Krishna, Reidhaar-Olson, John F., Rueger, Ruediger, Hilton, Holly

Volltext

Molecular Mechanisms of Bone Metastasis von Weidle, Ulrich H, Birzele, Fabian, Kollmorgen, Gwendlyn, Ruger, Rudiger

Volltext

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tum... von Martinez-Garcia, Maria, Banerji, Udai, Albanell, Joan, Bahleda, Rastilav, Dolly, Saoirse, Kraeber-Bodéré, Françoise, Rojo, Federico, Routier, Emilie, Guarin, Ernesto, Xu, Zhi-Xin, Rueger, Ruediger, Tessier, Jean J L, Shochat, Eliezer, Blotner, Steve, Naegelen, Valerie Meresse, Soria, Jean-Charles

Volltext

Dissection of the Process of Brain Metastasis Reveals Targets and Mechanisms for Molecular-based Intervention von Weidle, Ulrich H, Birzele, Fabian, Kollmorgen, Gwendlyn, Ruger, Rudiger

Volltext

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors von LEIJEN, Suzanne, MIDDLETON, Mark R, TESSIER, Jean J. L, SHOCHAT, Eliezer, BLOTNER, Steve, MERESSE NAEGELEN, Valerie, SCHELLENS, Jan H. M, EBERHARDT, Wilfried Ernst Erich, TRESCA, Patricia, KRAEBER-BODERE, Françoise, DIERAS, Veronique, SCHEULEN, Max E, GUPTA, Avinash, LOPEZ-VALVERDE, Vanesa, XU, Zhi-Xin, RUEGER, Ruediger

Volltext

MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia von Zhong, Hua, Chen, Gong, Jukofsky, Lori, Geho, David, Han, Sung Won, Birzele, Fabian, Bader, Sabine, Himmelein, Lucia, Cai, James, Albertyn, Zayed, Rothe, Mark, Essioux, Laurent, Burtscher, Helmut, Middleton, Steven A., Rueger, Ruediger, Chen, Lin‐Chi, Dangl, Markus, Nichols, Gwen, Pierceall, William E.

Volltext

Loss of diphthamide pre-activates NF-[kappa]B and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor von Stahl, Sebastian, Seidl, Ana Rita da Silva Mateus, Ducret, Axel, van Geijtenbeek, Sabine Kux, Michel, Sven, Racek, Tomas, Birzele, Fabian, Haas, Alexander K, Rueger, Ruediger, Gerg, Michael, Niederfellner, Gerhard, Pastan, Ira, Brinkmann, Ulrich

Volltext

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells von Reis, Bernhard, Jukofsky, Lori, Chen, Gong, Martinelli, Giovanni, Zhong, Hua, So, Venus, Dickinson, Michael J., Drummond, Mark W., Assouline, Sarit E., Hashemyan, Maneja, Theron, Michel, Blotner, Steven, Lee, Je-Hwan, Kasner, Margaret, Yoon, Sung-Soo, Rueger, Ruediger, Seiter, Karen, Middleton, Steven, Kelly, Kevin R., Vey, Norbert, Yee, Karen W.L., Nichols, Gwen, Chen, Lin-Chi, Pierceall, William E.

Volltext

Results of the Phase 1 Trial of RG7112, a Small-molecule MDM2 Antagonist in Leukemia von Andreeff, Michael, Kelly, Kevin R., Yee, Karen, Assouline, Sarit, Strair, Roger, Popplewell, Leslie, Bowen, David, Martinelli, Giovanni, Drummond, Mark W., Vyas, Paresh, Kirschbaum, Mark, Iyer, Swaminathan Padmanabhan, Ruvolo, Vivian, Nogueras González, Graciela M., Huang, Xuelin, Chen, Gong, Graves, Bradford, Blotner, Steven, Bridge, Peter, Jukofsky, Lori, Middleton, Steve, Reckner, Monica, Rueger, Ruediger, Zhi, Jianguo, Nichols, Gwen, Kojima, Kensuke

Volltext

MDM 2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia von Zhong, Hua, Chen, Gong, Jukofsky, Lori, Geho, David, Han, Sung Won, Birzele, Fabian, Bader, Sabine, Himmelein, Lucia, Cai, James, Albertyn, Zayed, Rothe, Mark, Essioux, Laurent, Burtscher, Helmut, Middleton, Steven A., Rueger, Ruediger, Chen, Lin‐Chi, Dangl, Markus, Nichols, Gwen, Pierceall, William E.

Volltext

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression von Lee, Lucy, Niu, Huifeng, Goelzer, Petra, Rueger, Ruediger, Deutsch, Jonathan, Busse-Reid, Rachel, DeSchepper, Stefanie, Blotner, Steve, Barrett, Joanne, Weissgerber, Georges, Peck, Richard

Volltext